Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc. U.S., submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational fixed-dose combination of azilsartan medoxomil plus chlorthalidone for the treatment of hypertension, or high blood pressure.

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP?„?) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP?„? molecule to protect against the attacks of the most hostile inflammation causing agents known.

Regeneron Pharmaceuticals, Inc. today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

Gastric bypass surgery appears to lead to better long-term results including greater weight loss, resolution of diabetes and improved quality of life compared with sleeve gastrectomy and "lap-band" surgery, according to two reports in the February issue of Archives of Surgery, one of the JAMA/Archives journals.

Rapid improvement in the socio-economic conditions of the Gulf states has been followed by lifestyle changes now contributing to high rates of cardiovascular disease. Professor Hani Najm, President of the Saudi Heart Association whose annual conference begins 21 February 2011, describes risk factor prevalence rates as "extremely high", particularly in the cities of Saudi Arabia.